US Patent Issued to MEMORIAL SLOAN-KETTERING CANCER CENTER on July 29 for "T cell receptors targeting PIK3CA mutations and uses thereof" (New York Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,371,467, issued on July 29, was assigned to MEMORIAL SLOAN-KETTERING CANCER CENTER (New York).

"T cell receptors targeting PIK3CA mutations and uses thereof" was invented by Christopher A. Klebanoff (New York) and Smita S. Chandran (Long Island City, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-targeted T cell receptors (TCRs) that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunorespon...